- $99.43bn
- $118.21bn
- £31.38bn
- 92
- 66
- 99
- 98
REG - GSK PLC - FDA accepts new drug application for gepotidacin
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Positive results of ANCHOR trials of depemokimab
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Zantac (ranitidine) litigation settlements
AnnouncementREG - GSK PLC - Positive efficacy data of Arexvy over 3 seasons
AnnouncementREG - Allianz Global Invs - Top 10 holdings
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Positive EU opinion for GSK liquid Menveo vaccine
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Japan Filing Acceptance: Blenrep Multiple Myeloma
AnnouncementREG - GSK PLC - China Breakthrough Therapy Designation for Blenrep
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Positive mRNA flu vaccine Phase II headline data
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Change of Registered Office
AnnouncementREG - GSK PLC - Update on phase I/II therapeutic HSV vaccine trial
Announcement